Wall Street Zen Downgrades Theravance Biopharma (NASDAQ:TBPH) to Hold

Wall Street Zen cut shares of Theravance Biopharma (NASDAQ:TBPH - Free Report) from a buy rating to a hold rating in a research report report published on Saturday morning.

Other equities research analysts also recently issued research reports about the company. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a research report on Tuesday, June 17th. BTIG Research boosted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Theravance Biopharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded down $0.16 during trading on Friday, hitting $11.30. The company's stock had a trading volume of 179,091 shares, compared to its average volume of 261,652. The stock has a market capitalization of $565 million, a price-to-earnings ratio of -9.58 and a beta of -0.02. The stock's fifty day moving average is $10.30 and its 200 day moving average is $9.60. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. On average, research analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president owned 336,918 shares in the company, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Aquatic Capital Management LLC acquired a new position in shares of Theravance Biopharma in the fourth quarter worth about $25,000. GAMMA Investing LLC lifted its stake in shares of Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 3,281 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Theravance Biopharma in the fourth quarter worth about $69,000. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the first quarter worth about $101,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the fourth quarter worth about $103,000. Institutional investors and hedge funds own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.